Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | New targets in relapsed/refractory multiple myeloma patients

Dr Sagar Lonial, MD from Emory University, Atlanta, USA, updates us on treatments for patients with relapsed/refractory myeloma from the European Hematology 2017 in Madrid, Spain. Despite exciting advances, we are still seeing lots of patients in this category. Sagar tells us about the new targets that are very important for these patients, including XPO1 targeted by selinexor, PD1 partnered with IMiDs, CAR-T cells and BCMA.